A multicenter, randomized, double-blind, placebo-controlled, 8-week trial of the efficacy and tolerability of once-daily losartan 100 mg/hydrochlorothiazide 25 mg and losartan 50 mg/hydrochlorothiazide 12.5 mg in the treatment of moderate-to-severe essential hypertension

Clinical Therapeutics

Volumn 24, Issue 7, 2002, Pages 1049-1061

  Gradman, Alan H ^a   Brady, William E ^b   Gazdick, Lisa P ^b   Lyle, Paulette ^b   Zeldin, Robert K ^b  

^a WESTERN PENNSYLVANIA HOSPITAL   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Angiotensin II receptor antagonist; Hydrochlorothiazide; Hypertension; Losartan

Indexed keywords

HYDROCHLOROTHIAZIDE PLUS LOSARTAN; PLACEBO; ANGIOTENSIN RECEPTOR; ANTIHYPERTENSIVE AGENT; HYDROCHLOROTHIAZIDE; LOSARTAN;

ADULT; AGED; ARTICLE; ASTHENIA; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ESSENTIAL HYPERTENSION; FACE EDEMA; FATIGUE; FEMALE; HEADACHE; HUMAN; HYPERTENSION; HYPOTENSION; LACRIMATION; LEG EDEMA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STATISTICAL SIGNIFICANCE; SYNCOPE; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; VERTIGO; BLOOD PRESSURE; COMPARATIVE STUDY; DRUG ANTAGONISM; DRUG COMBINATION; DRUG EFFECT; HOSPITALIZATION; MIDDLE AGED; PULSE RATE;

ADULT; AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; FEMALE; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; LOSARTAN; MALE; MIDDLE AGED; PULSE; RECEPTORS, ANGIOTENSIN; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 0036022902     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(02)80018-2     Document Type: Article

References (16)

1. 1999 World Health Organization-International Society of Hypertension guidelines for the management of hypertension
2. Blood pressure, stroke, and coronary heart disease. Part 2, short-term reductions in blood pressure: Overview of randomised drug trials in their epidemiological context
3. Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988-1991
4. Department of Veterans Affairs single-drug therapy of hypertension study. Revised figures and new data
5. Losartan potassium: A review of its pharmacology, clinical efficacy and tolerability in the management of hypertension
6. Efficacy, tolerability, and effects on quality of life of losartan, alone or with hydrochlorothiazide, versus amlodipine, alone or with hydrochlorothiazide, in patients with essential hypertension
7. Increased efficacy and tolerability with losartan plus hydrochlorothiazide in patients with uncontrolled hypertension and therapy-related symptoms receiving two monotherapies
8. A randomized, placebo-controlled, double-blind, parallel study of various doses of losartan potassium compared with enalapril maleate in patients with essential hypertension
9. Efficacy and tolerability of losartan potassium and atenolol in patients with mild to moderate essential hypertension
10. Antihypertensive efficacy and safety of losartan alone and in combination with hydrochlorothiazide in adult African Americans with mild to moderate hypertension
11. The efficacy and tolerability of losartan versus atenolol in patients with isolated systolic hypertension
12. The effect of a losartan-based treatment regimen on isolated systolic hypertension
13. Human blood pressure determination by sphygmomanometry
14. Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial
15. Effects of losartan on a background of hydrochlorothiazide in patients with hypertension